The 2018 China Healthcare Investment and Partnering Symposium was held in Hangzhou yesterday, attracting 43 NASDAQ-listed companies and 19 enterprises in industries of bioengineering, pharmaceutical and medical equipment from Europe and America.
More than 300 pharmaceutical enterprises and medical investment institutions from China also signed up to join the four-day symposium, which focuses on the bioengineering and pharmaceutical innovations and capital investment.
Guests attending the opening ceremony witnessed the signing of China Special Opportunity Fund for Medical and Healthcare (Cross-border) and NASDAQ Innovative Medicine Enterprise (Hangzhou) Service Center.
With a total size of 1 billion yuan (US$156.25 million), China Special Opportunity Fund for Medical and Healthcare (Cross-border) aims to provide financial support for foreign and domestic medicine and technology suppliers to settle down in Hangzhou, focusing on innovative technologies in medical equipment as well as high and new technology enterprises with strong competitive capability.
NASDAQ Innovative Medicine Enterprise (Hangzhou) Service Center will provide a wide range of services, including market research, financing for joint venture companies, certification by the China Food and Drug Administration, and listing preparations for domestic companies on overseas exchanges.